Published in

American Association for Cancer Research, Cancer Immunology Research, 8(10), p. 918-918, 2022

DOI: 10.1158/2326-6066.cir-22-0473

Links

Tools

Export citation

Search in Google Scholar

Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?

Journal article published in 2022 by Margaux Hubert ORCID, Christophe Caux ORCID, Jenny Valladeau-Guilemond ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractIn this issue of Cancer Immunology Research, Ferris and colleagues demonstrate that type 1 conventional DC (cDC1) vaccines drive tumor rejection through direct antigen presentation, without the need of endogenous cDC1. This suggests that cDC1-based vaccines could represent an optimal strategy to induce antitumor immunity in patients.See related article by Ferris et al., p. 920 (7) .